Erbitux Solution
Product Images NDC 66733-948

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Erbitux (NDC 66733-948). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Imclone Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Erbitux 100mg Vial (Erbitux 100mg 009 02)

FDA Label Image

Erbitux 200mg Vial (Erbitux 200mg 010 03)

Erbitux 200mg Vial (Erbitux 200mg 010 03)
This text seems to be a mixture of medical-related information, including dosage and administration instructions, and drug details for Erbitux, a medication available in injectable form for intravenous use. It also contains information such as the composition and volume of a single dose, as well as its contents and some control numbers used for inventory purposes.*
FDA Label Image

Figure 1 (Erbitux Uspi F1v1)

Figure 1 (Erbitux Uspi F1v1)
This looks like a table showing the proportion of patients alive over time, separated by treatment groups (CET+CT and cT). The time is measured in months, and the number of patients at risk is listed for each time point. However, the data seems to be incomplete as the text in the second row appears to be garbled.*
FDA Label Image

Figure 2 (Erbitux Uspi F2v1)

Figure 2 (Erbitux Uspi F2v1)
The given text represents a chart or graph showing the proportion of patients alive over time, measured in months. The chart includes two groups of patients: "CET+CT" and "cT". The number of patients at risk (i.e. still being monitored) is also given for each time point for both groups.*
FDA Label Image

Figure 3 (Erbitux Uspi F3v1)

FDA Label Image

Erbitux Uspi F4v1

Erbitux Uspi F4v1
This is a graph showing the probability of survival for patients taking ERBITUX and encorafenib compared to the control group. The horizontal axis represents time, and the vertical axis represents the probability of survival. The number of patients at risk is shown below the graph.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.